Probiotics manipulate host cytokine response and induce antimicrobial peptides

Folia Microbiologica

Volumn 51, Issue 5, 2006, Pages 507-510

  Trebichavsky I ^a   Splichal I ^a  

^a INSTITUTE OF MICROBIOLOGY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMICROBIAL CATIONIC PEPTIDE; CYTOKINE; PROBIOTIC AGENT;

ARTICLE; BIFIDOBACTERIUM; HUMAN; IMMUNOLOGY; LACTOBACILLUS; METABOLISM;

ANTIMICROBIAL CATIONIC PEPTIDES; BIFIDOBACTERIUM; CYTOKINES; HUMANS; LACTOBACILLUS; PROBIOTICS;

EID: 33751323464     PISSN: 00155632     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02931599     Document Type: Article

References (50)

1. BAMBOU J.C., GIRAUD A., MENARD S., BEGUE B., RAKATOBE S., HEYMAN M., TADDEI F., CERF-ENSUSSAN N., GABORIAU-ROUTHIAU V.: In vitro and ex vivo activation of the TLR5 signaling pathway in intestinal epithelial cells by a commensal Escherichia coli strain. J.Biol.Chem. 279, 42984-42992 (2004).
2. BROUSSERD E.K., SURAWICZ C.M.: Probiotics and prebiotics in clinical practice. Nutr.Clin.Care 7, 104-113 (2004).
3. BUJŇÁKOVÁ D., VLKOVÁ E., RADA V., KMEŤ V.: Aggregation of lactobacilli and bifidobacteria with Escherichia coli O157. Folia Microbiol. 49, 143-146 (2004).
4. CHEN C.C., LOUIE S., SHI H.N., WALKER W.A.: Preinoculation with the probiotic Lactobacillus acidophilus early in life effectively inhibits murine Citrobacter rodentium colitis. Pediatr.Res. 58, 1185-1191 (2005).
5. CROSS M.L., GANNER A., TEILAB D., FRAY L.M.: Patterns of cytokine induction by Gram-positive and Gram-negative probiotic bacteria. FEMS Immunol.Med.Microbiol. 42, 173-180 (2004).
6. CUKROWSKA B., LODINOVÁ-ŽÁDNÍKOVÁ R., ENDERS C., SONNENBORN U., SCHULZE J., TLASKALOVÁ-HOGENOVÁ H.: Specific proliferative and antibody responses of premature infants to intestinal colonization with nonpathogenic probiotic E. coli strain Nissle 1917. Scand.J.Immunol. 55, 204-209 (2002).
7. DI CARO S., TAO H., GRILLO A., ELIA C., GASBARRINI G., SEPULVEDA A.R., GASBARRINI A.: Effect of Lactobacillus GG on genes expression pattern in small bowel mucosa. Dig.Liver Dis. 37, 320-329 (2005).
8. H1-mediated murine colitis by inducing IL-10 and IL-10-dependent TGF-β-bearing regulatory cells. J.Immunol. 174, 3237-3246 (2005).
9. DOTAN I., RACHMILEWITZ D.: Probiotics in inflammatory bowel disease: possible mechanisms of action. Curr.Opin.Gastroenterol. 21, 426-430 (2005).
10. FLOCH M.H.: Probiotics, irritable bowel syndrome, and inflammatory bowel disease. Curr.Treat.Options Gastroenterol. 6, 283-288 (2003).
11. GORBACH S.L.: Probiotics and gastrointestinal health. Am.J.Gastroenterol. 95 (Suppl. 1), S2-S4 (2000).
12. HART A.L., LAMMERS K., BRIGIDI P., VITALI B., RIZZELLO F., GIONCHETTI P., CAMPIERI M., KAMM M.A., KNIGHT S.C., STAGG A.J.: Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut 53, 1602-1609 (2004).
13. HOCKERTZ S.: Augmentation of host defense against bacteria and fungal infections of mice pretreated with the non-pathogenic Escherichia coli strain Nissle 1917. Arzneimittelforschung, 47, 793-796 (1991).
14. KALLIOMAKI M., SALMINEN S., POUSSA T., ARVILOMMI H., ISOLAURI E.: Probiotics and prevention of atopic disease: 4-year follow-up of a randomized placebo-controlled trial. Lancet 361, 1869-1871 (2003).
15. KOZÁKOVÁ H., ŘEHÁKOVÁ Z., KOLÍNSKÁ J.: Bifidobacterium bifidum monoassociation of gnotobiotic mice: effect on enterocyte brush-border enzymes. Folia Microbiol. 46, 573-576 (2001).
16. KRAMMER H.J., SCHLIEGER F., HARDER H., FRANKE A., SINGER M.V.: Probiotics as therapeutic agents in irritable bowel syndrome. Z.Gastroenterol. 43, 467-471 (2005).
17. KRUIS W., FRIČ P., POKROTNIEKS J., LUKÁŠ M., FIXA B., KAŠČÁK M., KAMM M.A., WEISMUELLER J., BEGLINGER C., STOLTE M., WOLFF C., SCHULZE J.: Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53, 1617-1623 (2004).
18. LAMMERS K.M., HELWIG U., SWENNEN E., RIZZELLO F., VENTURI A., CARAMELLI E., KAMM M.A., BRIGIDI P., GIONCHETTI P., CAMPIERI M.: Effect of probiotic strains on interleukin 8 production by HT29/19A cells. Am.J.Gastroenterol. 97, 1182-1186 (2002).
19. LILLY D.M., STILLWELL R.H.: Probiotics: growth promoting substances produced by microorganisms. Science 147, 747-748 (1965).
20. LODINOVÁ-ŽÁDNÍKOVÁ R., SONNENBORN U.: Effect of preventive administration of a nonpathogenic Escherichia coli strain on the colonization of the intestine with microbial pathogens in newborn infants. Biol.Neonate 71, 224-232 (1997).
21. LODINOVÁ-ŽÁDNÍKOVÁ R., SONNENBORN U., TLASKALOVÁ H.: Probiotics and E. coli infections in man. Vet.Quart. 20 (Suppl. 3), S78-S81 (1998).
22. LODINOVÁ-ŽÁDNÍKOVÁ R., CUKROWSKA B., TLASKALOVÁ-HOGENOVÁ H.: Oral administration of probiotic Escherichia coli after birth reduces frequency of allergies and repeated infections later in life (after 10 and 20 years). Internat.Arch.Allergy Immunol. 131, 209-211 (2003).
23. MANDEL L., TREBICHAVSKÝ I., ŠPLÍCHAL I., SCHULZE J.: Stimulation of intestinal immune cells by E. coli in gnotobiotic piglets, pp. 463-464 in Advances in Mucosal Immunology (J. Mestecky, M.W. Rusell, S. Jackson, S.M. Michalek, H. Tlaskalová-Hogenová, J. Šterzl, Eds). Plenum Press, New York-London 1995.
24. MATTAR M.A., CORTINAS T.I., DE GUZMAN A.M.: Immunogenic protein variations of Clostridium chauvoei cellular antigens associated with the culture growth phase. FEMS Immunol.Med.Microbiol. 33, 9-14 (2002).
25. MEGO M., MÁJEK J., KONČEKOVÁ R., EBRINGER L., ČIERNIKOVÁ S., RAUKO P., KOVÁČ M., TRUPL J., SLEZÁK P., ZAJAC V.: Intramucosal bacteria in colon cancer and their elimination by probiotic strain Enterococcus faecium M-74 with organic selenium. Folia Microbiol. 50, 443-447 (2005).
26. METCHNIKOFF E.: Lactic acid as inhibiting intestinal putrefaction, pp. 161-183 in The Prolongation of Life: Optimistic Studies (P. Chalmers Mitchell, Ed.). Heinemann, London 1907.
27. MLČKOVÁ P., ČECHOVÁ D., MARUŠ KOVÁ L., CHALUPNÁ P., NOVOTNÁ O., PROKEŠOVÁ L.: Role of T cells in the adjuvant effect of Bacillus firmus on the immune system of mice: intranasal and intratracheal immunization study with ovalbumin. Folia Microbiol. 48, 427-434 (2003).
28. MLČKOVÁ P., POLÁČEK M., ČECHOVÁ D., MARUŠKOVÁ L., STAŇKOVÁ I., CHALUPNÁ P., NOVOTNÁ O., JULÁK J., PROKEŠOVÁ L.: Intratracheal and intranasal immunization with ovalbumin conjugated with Bacillus firmus as a carrier in mice. Folia Microbiol. 50, 247-254 (2005).
29. NIERS L.E., TIMMERMAN H.M., RIJKERS G.T., VAN BLEEK G.M., VAN UDEN N.O., KNOL E.F., KAPSENBERG M.L., KIMPEN J.L., HOEKSTRA M.O.: Identification of strong interleukin-10 inducing lactic acid bacteria which down-regulate T helper type 2 cytokines. Clin.Exp.Allergy 35, 1481-1489 (2005).
30. NISSLE A.: Die antagonistische Behandlung chronischer Darmstorungen mit Colibacterien. Med.Klinik 2, 29-30 (1918).
31. O'MAHONY L., O'CALLAGHAN L., MCCARTHY J., SHILLING D., SCULLY P., SIBARTIE S., KAVANAGH E., KIRWAN W.O., REDMOND H.P., COLLINS J.K., SHANAHAN F.: Differential cytokine response from dendritic cells to commensal and pathogenic bacteria in different lymphoid compartments in humans. Am.J.Physiol. Gastrointest.Liver Physiol. 290, G839-G845 (2006).
32. OTTE J.M., ROSENBERG I.M., PODOLSKY D.K.: Intestinal myofibroblasts in innate immune responses of the intestine. Gastroenterology 124, 1866-1878 (2003).
33. PETROF E.O., KOJIMA K., ROPELESKI M.J., MUSCH M.W., TAO Y., DE S.C., CHANG E.B.: Probiotics inhibit nuclear factor κB and induce heat-shock proteins in colonic epithelial cells through proteasome inhibition. Gastroenterology 127, 1474-1487 (2004).
34. PROKEŠOVÁ L., MLČKOVÁ P., STAŇKOVÁ I., LADMANOVÁ P., JEŽKOVÁ J., CHALUPNÁ P., NOVOTNÁ O., ČECHOVÁ D., JULÁK J.: Immunostimulatory effect of Bacillus firmus on mouse lymphocytes. Folia Microbiol. 47, 193-197 (2002).
35. RACHMILEWITZ D., KATAKURA K., KARMELI F., HAYASHI T., REINUS C., RUDENSKY B., AKIRA S., TAKEDA K., LEE J., TAKABAYASHI K., RAZ E.: Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 126, 520-528 (2004).
36. ROVENSKÝ J., ŠVÍK K., STANČÍ KOVÁ M., ISTOK R., EBRINGER L., FERENČÍK M.: Treatment of experimental adjuvant arthritis with the combination of methotrexate and lyophilized Enterococcus faecium enriched with organic selenium. Folia Microbiol. 47, 573-578 (2002).
37. SARTOR R.B.: Probiotic therapy of intestinal inflammation and infections. Curr.Opin.Gastroenterol. 21, 44-50 (2005).
38. SCHULTZ M., STRAUCH U.G., LINDE H.J., WATZL S., OBERMAIER F., GOTTL C., DUNGER N., GRUNWALD N., SCHOLMERICH J., RATH H.C.: Preventive effects of Escherichia coli strain Nissle 1917 on acute and chronic intestinal inflammation in two different murine models of colitis. Clin.Diagn.Lab.Immunol. 11, 372-378 (2004).
39. SEIFERT H.S., GESSLER F.: Oral long-term administration of probiotic B. cereus - an alternative for the prevention of enterotoxemia. Deutsch.Tierarztl.Wochenschr. 103, 386-389 (1996).
40. SENOK A.C., ISMAEEL A.Y., BOTTA G.A.: Probiotics: facts and myths. Clin.Microbiol.Infect. 11, 958-966 (2005).
41. ŠÍMA P., TREBICHAVSKÝ I., SIGLER K.: Mammalian antibiotic peptides. Folia Microbiol. 48, 123-137 (2003a).
42. ŠÍMA P., TREBICHAVSKÝ I., SIGLER K.: Nonmammalian vertebrate antibiotic peptides. Folia Microbiol. 48, 709-724 (2003b).
43. ŠPLÍCHAL I., FAGERHOL M.K., TREBICHAVSKÝ I., ŠPLÍCHALOVÁ A., SCHULZE J.: The effect of intestinal colonization of germ-free pigs with Escherichia coli on calprotectin levels in plasma, intestinal and bronchoalveolar lavages. Immunobiology 209, 681-687 (2005a).
44. ŠPLÍCHAL I., TREBICHAVSKÝ I., ŠPLÍ CHALOVÁ A., BARROW P.A.: Protection of gnotobiotic pigs against Salmonella enterica serotype Typhimurium by rough mutant of the same serotype is accompanied by the change of local and systemic cytokine response. Vet.Immunol.Immunopathol. 103, 155-161 (2005b).
45. STŘÍŽ I., TREBICHAVSKÝ I.: Calprotectin - a pleiotropic molecule in acute and chronic inflammation. Physiol.Res. 53, 245-253 (2004).
46. STROMPFOVÁ V., LAUKOVÁ A., OUWEHAND A.C.: Lactobacilli and enterococci - potential probiotics for dogs. Folia Microbiol. 49, 203-208 (2004).
47. STURM A., RILLING K., BAUMGART D.C., GARGAS K., BOU-GHAZALE T., RAUPACH B., ECKERT J., SCHUMANN R.R., ENDERS C., SONNENBORN U., WIEDENMANN B., DIGNASS A.U.: Escherichia coli Nissle 1917 distinctively modulates T-cell cycling and expansion via toll-like receptor 2 signaling. Infect.Immun. 73, 1452-1465 (2005).
48. VAARALA O.: Immunological effects of probiotics with special reference to lactobacilli. Clin.Exp.Allergy 33, 1634-1640 (2003).
49. VAN DER WAAIJ D.: The role of microbial flora in the development, maintenance and modulation of the immune function. Adv.Physiol.Sci. 29, 443-477 (1980).
50. WEHKAMP J., HARDES J., WEHKAMP K., WEHKAMP-VON MEISSNER B., SCHLEE M., ENDERS C., SONNENBORN U., NUDING S., BENGMARK S., FELLERMANN K., SCHRODER J.M., STANGE E.F.: NF-κB- and AP-1-mediated induction of human β-defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect.Immun. 72, 5750-5758 (2004).